Crystalline solvate and non-solvated forms of 6,6′-[[3,3′,5,5′-tetrakis(1,1-dimethylethyl)-[1,1′biphenyl]-2,2′-diyl]bis(oxy)]bis-dibenzo [d,f] [1,3,2]-dioxaphosphepine
AssigneeBASF SE
InventorsUlrich Berens, Holger Ganz, Tiziana Chiodo
Life of this patent
Estimating the term…
Abstract
The present invention relates to a crystalline non-solvated form of 6,6′-[[3,3′,5,5′-tetrakis(1,1-dimethylethyl)-[1,1′-biphenyl]-2,2′-diyl]bis(oxy)]bis-dibenzo[d,f][1,3,2]-dioxaphosphepine (compound I) and toluene-solvates and acetone-solvates thereof.
Claims28
A crystalline non-solvated form of 6,6′-[[3,3′,5,5′-tetrakis(1,1-dimethylethyl)-[1,1′-biphenyl]-2,2′-diyl]bis(oxy)]bis-dibenzo[d,f][1,3,2]-dioxaphosphepine (compound I) and toluene-solvates and acetone-solvates thereof.
A crystalline toluene-monosolvate of 6,6′-[[3,3′,5,5′-tetrakis(1,1-dimethylethyl)-[1,1′-biphenyl]-2,2′-diyl]bis(oxy)]bis-dibenzo[d,f][1,3,2]-dioxaphosphepine, which in an X-ray powder diffractogram at 25° C. with Cu—Kα radiation displays at least 5 of the following reflections, stated as 2θ values:
- 5.15±0.20°, 7.59±0.20°, 8.56±0.20°, 8.80±0.20°, 8.97±0.20°, 9.65±0.20°, 10.55±0.20°, 11.47±0.20°, 14.76±0.20° and 15.35±0.20.
A non-solvated crystalline form of 6,6′-[[3,3′,5,5′-tetrakis(1,1-dimethylethyl)-[1,1′-biphenyl]-2,2′-diyl]bis(oxy)]bis-dibenzo[d,f][1,3,2]-dioxaphosphepine, which in an X-ray powder diffractogram at 25° C. with Cu—Kα radiation displays at least 5 of the following reflections, stated as 2θ values:
- 5.39±0.20°, 7.04±0.20°, 8.44±0.20°, 8.65±0.20°, 9.08±0.20°, 9.66±0.20°, 10.66±0.20°, 12.60±0.20°, 16.25±0.20° and 17.36±0.20°.
A crystalline acetone-solvate “A” of 6,6′-[[3,3′,5,5′-tetrakis(1,1-dimethylethyl)-[1,1′-biphenyl]-2,2′-diyl]bis(oxy)]bis-dibenzo[d,f][1,3,2]-dioxaphosphepine, which in an X-ray powder diffractogram at 25° C. with Cu—Kα radiation displays at least 5 of the following reflections, stated as 2θ values:
- 6.67±0.20°, 7.11±0.20°, 7.87±0.20°, 8.31±0.20°, 8.96±0.20°, 9.17±0.20°, 10.68±0.20°, 15.78±0.20°, 16.10±0.20° and 18.63±0.20°.
A crystalline acetone-solvate “B” of 6,6′-[[3,3′,5,5′-tetrakis(1,1-dimethylethyl)-[1,1′-biphenyl]-2,2′-diyl]bis(oxy)]bis-dibenzo[d,f][1,3,2]-dioxaphosphepine, which in an X-ray powder diffractogram at 25° C. with Cu—Kα radiation displays at least 5 of the following reflections, stated as 2θ values:
- 8,13±0,2, 8,70±0,2°, 8,95±0,2°, 10,02±0,2°, 10,98±0,2°, 11,71±0,2°, 14,16±0,2°, 15,65±0,2°, 16,98±0,2° and 18,08±0,2°.
A crystalline acetone-solvate “C” of 6,6′-[[3,3′,5,5′-tetrakis(1,1-dimethylethyl)-[1,1′-biphenyl]-2,2′-diyl]bis(oxy)]bis-dibenzo[d,f][1,3,2]-dioxaphosphepine, which in an X-ray powder diffractogram at 25° C. with Cu—Kα radiation displays at least 5 of the following reflections, stated as 2θ values:
- 5.40±0.20°, 6.97±0.20°, 7.64±0.20°, 8.39±0.20°, 9.24±0.20°, 9.44±0.20°, 11.23±0.20°, 13.46±0.20°, 15.32±0.20° and 18.35±0.20°.
Dependencies are inferred from the claim text.